ImmunityBio, Inc. (NASDAQ:IBRX) Shares Purchased by Alliancebernstein L.P.

Alliancebernstein L.P. lifted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 4.1% during the fourth quarter, HoldingsChannel reports. The firm owned 214,030 shares of the company’s stock after purchasing an additional 8,500 shares during the quarter. Alliancebernstein L.P.’s holdings in ImmunityBio were worth $548,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Swiss National Bank increased its position in shares of ImmunityBio by 1.5% during the fourth quarter. Swiss National Bank now owns 274,000 shares of the company’s stock worth $701,000 after acquiring an additional 4,000 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in shares of ImmunityBio by 20.4% during the 4th quarter. Teacher Retirement System of Texas now owns 41,742 shares of the company’s stock valued at $107,000 after buying an additional 7,067 shares during the last quarter. Commonwealth Equity Services LLC increased its stake in shares of ImmunityBio by 40.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 28,955 shares of the company’s stock worth $74,000 after buying an additional 8,380 shares during the last quarter. E Fund Management Co. Ltd. boosted its stake in ImmunityBio by 32.9% during the 4th quarter. E Fund Management Co. Ltd. now owns 38,900 shares of the company’s stock valued at $100,000 after acquiring an additional 9,622 shares during the last quarter. Finally, Copperwynd Financial LLC increased its position in shares of ImmunityBio by 99.1% in the 4th quarter. Copperwynd Financial LLC now owns 20,087 shares of the company’s stock worth $51,000 after purchasing an additional 10,000 shares during the last quarter. 8.58% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on IBRX. BTIG Research started coverage on ImmunityBio in a report on Friday, January 10th. They issued a “buy” rating and a $6.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of ImmunityBio in a research note on Wednesday. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $30.00 price target on shares of ImmunityBio in a report on Tuesday, April 15th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $12.19.

ImmunityBio Stock Performance

Shares of IBRX opened at $2.47 on Friday. The company has a market cap of $2.11 billion, a price-to-earnings ratio of -2.68 and a beta of 0.51. The firm has a fifty day moving average of $2.95 and a 200-day moving average of $3.50. ImmunityBio, Inc. has a 1 year low of $2.28 and a 1 year high of $10.53.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.11. The business had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million. Analysts predict that ImmunityBio, Inc. will post -0.92 EPS for the current year.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.